M&A Deal Summary |
|
|---|---|
| Date | 2016-07-26 |
| Target | Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors |
| Sector | Life Science |
| Buyer(s) | Trek Therapeutics PBC |
| Sellers(s) | Vertex Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
Trek Therapeutics, PBC is a clinical stage public benefit corporation developing treatments for serious infections. Trek Therapeutics mission is to develop affordable and accessible medicines to treat infectious diseases and to commercialize them for global populations.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1989 |
| Sector | Life Science |
| Employees | 6,100 |
| Revenue | 11.0B USD (2024) |
Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-11-20 |
INCIVO
United States INCIVO is a prescription medicine used with the medicines peginterferon alfa and ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1 infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment. |
Sell | $152M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-03-06 |
Concert Pharmaceuticals - CTP-656
Lexington, Massachusetts, United States Concert Pharmaceuticals, Inc. - CTP-656 was developed by Concert through the application of deuterium chemistry to modify Vertex’s CFTR potentiator, ivacaftor. Ivacaftor was discovered by Vertex scientists and is approved in the U.S., Europe, Canada and Australia for people with CF who have specific mutations in the CFTR gene. CTP-656 has the potential to play a key role in future once-daily combination regimens to treat CF. Concert is currently conducting a Phase 2 study of CTP-656 in people with CF who have gating mutations. As part of the agreement, Vertex will acquire rights to all of Concert’s other CF research and preclinical programs. |
Buy | $160M |
